SIC
ARCT icon

Salem Investment Counselors’s Arcturus Therapeutics ARCT Stock Holding History

Salem Investment Counselors’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-130
Closed -$4.1K – 1172
2023
Q4 		$4.1K Hold
130
– – ﹤0.01% 931
2023
Q3 		$3.32K Hold
130
– – ﹤0.01% 934
2023
Q2 		$3.73K Buy
130
+30
+30% +$817 ﹤0.01% 948
2023
Q1 		$2.4K Hold
100
– – ﹤0.01% 970
2022
Q4 		$1.7K Hold
100
– – ﹤0.01% 966
2022
Q3 		$1K Hold
100
– – ﹤0.01% 979
2022
Q2 		$2K Hold
100
– – ﹤0.01% 962
2022
Q1 		$3K Hold
100
– – ﹤0.01% 884
2021
Q4 		$4K Hold
100
– – ﹤0.01% 943
2021
Q3 		$5K Hold
100
– – ﹤0.01% 841
2021
Q2 		$3K Hold
100
– – ﹤0.01% 811
2021
Q1 		$4K Buy
+100
New +$5.96K ﹤0.01% 762

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Salem Investment Counselors's ARCT Position: Q1 2024 in Review

Salem Investment Counselors sold out of Arcturus Therapeutics (ARCT) in Q1 2024, closing a stake of 130 shares — an estimated $4.1K sold.

Salem Investment Counselors first reported a position in ARCT in Q1 2021 and held it in 12 quarters. The position peaked at $5K in Q3 2021. 179 funds tracked by Wall St. Rank hold ARCT as of Q1 2024.

  • Salem Investment Counselors reported no remaining Arcturus Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Salem Investment Counselors sold 130 Arcturus Therapeutics shares in Q1 2024, an estimated $4.1K.
  • Salem Investment Counselors first reported a position in Arcturus Therapeutics in Q1 2021 and held it in 12 quarters.
  • Salem Investment Counselors's Arcturus Therapeutics position peaked at $5K in Q3 2021.
  • 179 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2024.

Based on Salem Investment Counselors's 13F filing for Q1 2024, filed 11 Apr 2024.